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Abstract
Purpose We evaluated myelin changes throughout the central nervous system in Multiple Sclerosis (MS) patients by using
hybrid [18F]florbetapir PET-MR imaging.
Methods We included 18 relapsing-remitting MS patients and 12 healthy controls. Each subject performed a hybrid
[18F]florbetapir PET-MR and both a clinical and cognitive assessment. [18F]florbetapir binding was measured as distribution
volume ratio (DVR), through the Logan graphical reference method and the supervised cluster analysis to extract a reference
region, and standard uptake value (SUV) in the 70–90 min interval after injection. The two quantification approaches were
compared. We also evaluated changes in the measures derived from diffusion tensor imaging and arterial spin labeling.
Results [18F]florbetapir DVRs decreased from normal-appearing white matter to the centre of T2 lesion (P < 0.001), correlated
with fractional anisotropy and with mean, axial and radial diffusivity within T2 lesions (coeff. = −0.15, P < 0.001, coeff. = −0.12,
P < 0.001 and coeff. = −0.16, P < 0.001, respectively). Cerebral blood flowwas reduced in white matter damaged areas compared
to white matter in healthy controls (−10.9%, P = 0.005). SUV70–90 and DVR are equally able to discriminate between intact and
damaged myelin (area under the curve 0.76 and 0.66, respectively; P = 0.26).
Conclusion Our findings demonstrate that [18F]florbetapir PET imaging canmeasure in-vivomyelin damage in patients withMS.
Demyelination inMS is not restricted to lesions detected through conventionalMRI but also involves the normal appearing white
matter. Although longitudinal studies are needed, [18F]florbetapir PET imaging may have a role in clinical settings in the
management of MS patients.
Keywords Multiple sclerosis . PET . [18F]florbetapir . Demyelination . Pathology
Introduction
Multiple Sclerosis (MS) usually presents with episodes of
transient neurological deficits, called ‘relapses’ [1]. Relapses
mirror the occurrence of focal areas of acute demyelination
within the brain, optic nerves and spinal cord [2].
Demyelination can cause axonal loss, which over time causes
permanent disability [3]. Demyelination can be qualitatively
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detected as areas of high signal on T2-weighted magnetic
resonance imaging (MRI) sequences or as low signal in T1-
weighted spin-echo images onMRI scans [4]. AdvancedMRI
techniques might provide a better insight into multiple sclero-
sis pathology. In example, diffusion tensor imaging enables us
to detect microstructural tissue damages in brain regions [5,
6], whereas arterial spin labelling provides a quantitative mea-
sure of the cerebral blood flow. However, conventional MRI,
diffusion tensor imaging and arterial spin labelling only rep-
resent indirect measures of tissue modifications and lack spec-
ificity towards myelin integrity. Therefore, although previous
studies have reported the association between brain micro-
structural changes and physical disability in MS, the effect
of demyelination on physical disability might not be
disentangled for other pathological factors such as axonal loss
or gliosis for the low specificity of MRI techniques.
Over the past years, positron emission tomography (PET)
imaging has become a promising modality to monitor the bio-
logical processes underlying MS pathology [7]. Radioligands
developed to measure amyloid-β pathology in grey matter for
Alzheimer’s disease, such as [11C]PIB, [18F]florbetaben and
[18F]florbetapir [8–10] also showed affinity for myelin protein.
This is due to the fact that these stilbene and benzothiazole
derivatives have a very flat structure, interacting with the sec-
ondary structure of myelin basic protein similarly to the way
they interact with amyloid [11, 12]. In fact, in healthy white
matter, myelin basic protein has a particular two-dimensional
secondary structure as it acts as a hinge between lipid bilayers.
InMS, this structure is damagedwhich, consequently, leads to a
decreased binding of amyloid-β PET tracers [13]. Therefore,
stilbene and benzothiazole derivatives, firstly used to explore
amyloid accumulation throughout grey matter in neurodegen-
erative disease, might be a better marker of demyelination com-
pared to MRI in MS [14].
Bodini and colleagues, used [11C]PIB PET to imagemyelin
using dynamic acquisitions that has a short half-life (about
20 min) that limits its clinical viability, whereas Fluorine-18
labelled PET tracers have longer half-life (about 120 min),
which allows for a clinical use in patients MS. However, by
combining PETandMRI Bodini and colleagues demonstrated
that myelin changes, detected with amyloid PET imaging,
within lesions was associated with physical disability [15].
Therefore, suggesting a relationship between myelin disrup-
tion and outcome.
In this study we adopted a hybrid PET-MR approach using
[18F]florbetapir PET to quantify myelin content in MS patients.
We investigated the relationship between [18F]florbetapir up-
take and MRI measures, e.g. diffusion tensor imaging and ar-
terial spin labelling together with standard measures of cortical
grey matter volume. Finally, we compared SUV70–90 analyses
with the DVR kinetic modelling to estimate the clinical appli-




Eighteen patients with a definite diagnosis of relapsing-
remitting MS according to the 2010 revised McDonalds
criteria [16] and twelve healthy controls were recruited in
the study at King’s College Hospital NHS Foundation Trust
and through advertisement. All participants were successfully
screened according to scanning safety criteria (http://www.
mrisafety.com; https://www.gov.uk/government/publications/
arsac-notes-for-guidance) and had no history of other
neurological or psychiatric disorders. All procedures
performed in studies involving human participants were
conducted in accordance with the principles of the
Declaration of Helsinki and national regulations. The study
was approved by the local Ethics Committee (London-South
East Research Ethics Committee).
All subjects underwent a battery of clinical assessments,
including the assessment of clinical disability through the ex-
panded disability status scale (EDSS), the Timed 25-ft walk
and the 9-Hole-Peg test. We also assessed the disease severity
through the MS severity score (MSSS) before PET-MRI scan.
OneMS patient dropped out because he was unable to tolerate
PET/MR scan due to trigeminal neuralgia. Demographic, clin-
ical and imaging characteristics of theMS patients and healthy
controls are summarized in Table 1.
PET-MRI acquisition
PET images were acquired using a 3-Tesla Magnetom
Biograph mMR PET/MR hybrid scanner (Siemens,
Erlangen, Germany) with a spatial resolution of 4.3 mm and
a FOVof 258 mm at St Thomas PET centre. After the intra-
venous bolus injection of approximately 300 MBq of
[18F]florbetapir, we performed a dynamic 90-min scan. PET
dynamic images included 27 frames of data (8 × 15, 3 × 60,
5 × 120, 5 × 300 and 5 × 600 seconds). MRI sequences includ-
ed pre- and pos t -gadol in ium three-d imens iona l
magnetization-prepared rapid gradient-echo T1 (three-D-
T1w MPRAGE, TR [repetition time]: 1700 msec, TE [echo
time]: 2.63msec, TI [inversion time]: 900 msec, flip angle: 9°,
pixel size: 1.1 × 1.1 × 1.1 mm), fast fluid-attenuated inversion
recovery (FLAIR, TR: 5000 msec, TE: 499 msec, TI:
1800 msec, pixel size: 1x1x1mm) and turbo spin-echo T2-
weighed images (T2w TSE, TR: 3200 msec, TE: 409 msec,
TI: 900 msec, pixel size: 1x1x1mm). For each subject a dif-
fusion tensor echo-planar imaging sequence was registered,
with generalized auto-calibrating partial parallel acquisition,
at 2-fold acceleration (TR: 9300 msec, TE: 88 msec, pixel
size: 1.9 × 1.9x2mm, acquisition matrix: 128 × 128, field of
view: 240 mm, n° of slice: 40; diffusion-sensitizing pulsed
magnetic field gradients were applied in 64 non-collinear
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directions, at two diffusion weightings; one at 1000s/mm2 and
the second at 0 s/mm2) and a single-shot gradient echo-planar
imaging sequence was used to assess cerebral blood perfusion
through pseudo-continuous arterial spin labelling (TR:
3750 msec, TE: 21.96 msec, pixel size: 4x4x4mm, field of
view: 256 mm, flip angle: 180°, number of slices: 26, label
duration: 1500, post label delay: 1800 ms, 30 tag control pair).
Image data analysis
[18F]florbetapir PET data
Individual PET frames were realigned to a common reference
frame with high signal-to-noise ratio, to perform an intra-
subject motion correction [17]. Fluorine-18 decay correction
was applied. We performed a reference region approach
through a supervised cluster method to avoid blood sampling,
which is a cumbersome and bothersome procedure for patients.
The supervised clustering algorithm for [18F]florbetapir was
implemented following procedures already applied to [11C]PIB
[18]. Specifically, each frame’s radioactivity was normalized
for every voxel in the brain by subtracting the mean frame
activity and dividing it by the frame standard deviation.
Three kinetic classes for [18F]florbetapir were defined for the
normalized PET dynamic sequence using the twelve healthy
controls, who received [18F]florbetapir PET in this study: nor-
mal appearing grey matter (class 1), blood pool (class 2) and
white matter (class 3). Class 1 and 3 were calculated from the
average of normalized time activity curve for [18F]florbetapir in
the grey matter and white matter mask respectively. Class 2
was defined by extracting the 30 voxels with the highest
[18F]florbetapir radioactivity concentration over the first 60 s
of PETacquisition, corresponding to the big blood vessels. The
supervised cluster algorithm performs multiple linear regres-
sions for each voxel in the grey matter in order to model its
kinetic as a linear combination of the predefined kinetic classes
for [18F]florbetapir. For each voxel the weight from each class
was calculated. Voxels with a class 1 weighted ratio higher than
0.9 were selected as reference regions and the time activity
curve in this area was calculated as the average of the non-
normalized voxel time activity curve.
Logan graphical reference method was applied at a voxel
level on PET scans in native space to produce a parametric
maps of [18F]florbetapir binding measured as the DVR [19].
[18F]florbetapir PETwas also quantified using standardized
uptake value (SUV) in the 70–90min after injection. SUV70–90
map was generated by correcting absolute radioactivity con-
centrations (C; kBq/ml) for subject body weight (BW; kg) and
injected dose (ID; MBq): SUV=C/(ID/BW). [18F]florbetapir
Table 1 Demographic, clinical
and radiological features of
multiple sclerosis patients and
healthy controls
Multiple sclerosis patients Healthy
controls
P
Number of subjects 12 18 –
Gender (male/female) 6/12 5/8 0.768
Age, mean ± SD (years) 43.89 ± 8 39.31 ± 9.17 0.150
Disease duration, mean ± SD (years) 10.97 ± 6.90 – –
Annualized relapse rate, mean ± SD 0.73 ± 0.41 – –
Disease modifying therapy No Treatment, N (%): 4 (22.2) – –
Teriflunomide, N (%): 1 (5.6) – –
Dimethyl fumarate, N (%): 5 (27.8) – –
Fingolimod, N (%): 4 (22.2) – –
Daclizumab, N (%): 1 (5.6) – –
Natalizumab, N (%): 1 (5.6) – –
Alemtuzumab, N (%): 2 (11.1) – –
Expandend disability status scale, mean ± SD 3.33 ± 1.25 – –
Multiple sclerosis severity score, mean ± SD 4.53 ± 1.77 – –
Timed 25-Foot walk, mean ± SD (sec.) 11.06 ± 4.45 6.23 ± 0.93 0.115
Nine-hole pegboard test, mean ± SD (sec.) 24.37 ± 5.60 18.83 ± 1.90 0.009
Normalized cortical grey matter,
mean ± SD (cm3)
631 ± 54 641 ± 52 0.617
Normalized normal appearing white matter,
mean ± SD (cm3)
735 ± 29 777 ± 34 0.001
T2 lesion load, mean ± SD (cm3) 4.92 ± 5.19 – –
‘Black hole’ lesion load, mean ± SD (cm3) 2.12 ± 2.16 – –
SD= Standard Deviation
*Only one patient presented a single gadolinium-enhancing lesion
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SUV70–90 in the cerebellar cortex was compared between MS
patients and healthy controls; if no differences were detected,
the SUVR map would be calculated.
Conventional MR images post-processing
The following regions of interest have been defined by two
experienced observers (A.C., Z.C.) on each subject’s image,
using Analyze medical imaging software (version 12, Mayo
Foundation AnalyzeDirect): (a) T1 lesions, defined as
hypointense areas in 3D-T1w MPRAGE compared to normal
appearing white matter (NAWM); (b) T2 lesions, defined as
hyperintense areas in FLAIR compared to NAWM; (c)
Gadolinium enhancing (Gd+) lesions; (d) inner in-plane 2D
perilesional layer outside T2 lesions (4 to 0 mm from the
lesion); (e) Outer in-plane 2D perilesional layer outside T2
lesions (8 to 4 mm from the lesion). Each T2 Lesion was also
divided in two infralesional layers. A third experienced oper-
ator (G.D.), blind to clinical information, solved discordances
between the two observers.
T2 lesions and T1 lesions were further classified according
to regional location (infratentorial, periventricular, white matter
lesions in the corona radiata, defined as white matter lesions to
differentiate among other lesion location, and juxtacortical) by
two experienced observers (A.C., Z.C.). To reduce potential
bias from partial volume effects lesions smaller than the PET
resolution were not considered and perilesional layers larger
than the PET resolution were excluded.
T1 lesions mask was used to perform a ‘lesion filling’ pro-
cedure [20] on the 3D-T1w MPRAGE. We used T1 filled
images for MS patients and T1 images for healthy controls to
segment brain tissues in white matter, grey matter and CSF
through the SPM12 software (Statistical Parametric Mapping
version 12; http://www.fil.ion.ucl.ac.uk/spm/software/spm12/)
with a probability of belonging to each tissue class higher than
90%. Cortical grey matter was calculated by subtracting the
deep grey matter mask, obtained through the FIRST tool
available in FMRIB Software Library (FSL; University of
Oxford, UK) [21], from the total grey matter mask. In order
to extract the cerebellum cortex as reference region for the
SUVR, grey matter was automatically segmented using the
multi-atlas propagation with enhanced registration (MAPER)
approach [22]. After visual inspection for multi-atlas propaga-
tion with enhanced registration segmentation errors, the cere-
bellum grey mater cortex was extracted. Cortical grey matter
volume and white matter volume, normalized for subject head
size, were estimated using SIENAX [23].
Advanced MR images post-processing
Gradient vector (bvec) and b-value (bval) files were produced
and merged to b matrix files to process DTI images.
Composition of mean diffusivity, fractional anisotropy, radial
diffusivity and axial diffusivity maps were undertaken using
tools from the FMRIB Software Library (FSL, https://fsl.
fmrib.ox.ac.uk/fsl/). FMRIB’s [24]. Top-up and eddy,
motion-susceptibility and eddy-current fields were generated
to correct for off-field resonance and movement-related dis-
tortions [25, 26]. Voxel-by-voxel diffusion tensors were ap-
plied to the diffusion-weighted image through DTIfit, gener-
ating the quantitative mean diffusivity, fractional anisotropy,
radial diffusivity and axial diffusivity maps. These maps were
linearly registered into the corresponding DVR parametric
map through FMRIB’s Linear Image Registration Tool
(FLIRT) [27].
CBF map was calculated following Alsop and colleagues
approach [28]. Once label and control images were corrected
for motion through MCFLIRT [27], CBF parametric map was
produced. CBF is measured in ml/100 g/min.
PET-MRI co-registration
MRI scans and DTI maps were linearly registered into the
corresponding DVR parametric maps through FLIRT. The
derived transformation matrix was applied to align each re-
gion of interest to subjects’ DVR parametric map. T2 and T1
lesions maps in DVR space were summed and the combined
mask was subtracted from the total white matter to obtain the
NAWMmask. In order to evaluate the CBF in damaged white
matter areas for healthy controls, we defined a DVR cut-off
for myelin integrity as the mean DVR in the white matter
minus 1.96 times the standard deviation, corresponding to
the 5th percentile. We selected for each patients’ DVR para-
metric map, voxels belonging to white matter with a DVR
value lower than the cut-off creating a binary mask. The
resulting mask corresponded to the myelin impaired white
matter regions and the remaining voxels were classified as
unaffected white matter. Both impaired and unaffected white
matter masks were linearly registered into the corresponding
CBF parametric map through FLIRT and the cerebral perfu-
sion was assessed. All analyses were performed in DVR space
to avoid partial volume effect for DVR map.
Statistical analysis
Statistical analyses were performed using Stata software (ver-
sion 13; StataCorp LP, College Station, TX). Variance homo-
geneity and Gaussianity were tested for each variable with
Shapiro-Wilk test.
Differences in white and grey matter [18F]florbetapir DVR
between MS patients and healthy controls were tested using a
general linear model including the group as factor of interest,
age and gender as covariates and DVR as the dependent vari-
able. Differences in [18F]florbetapir DVR betweenMS patients’
normal appearing, healthy controls’ white matter, and each de-
fined region of interest were assessed using a mixed-effect
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linear model including regions of interest as the factor of inter-
est, age and gender as covariates, the subject as the random
effect and the DVR as the dependent variable. The relationship
between lesion intensity on conventional T1 and T2 MRI im-
ages and DTI measures and [18F]florbetapir DVR values was
further explored using a mixed-effect linear model including
each lesion’s intensity or DTI measures as the factor of interest,
age and gender as covariates, the subject as the random effect,
and each lesion’s DVR as the dependent variable. The potential
additional value of DVR over fractional anisotropy asmeasured
through DTI in differentiating normal appearing white matter,
outer T2 perilesion layer and inner T2 lesion layer was investi-
gated via hierarchical linear regression analyses. In particular,
age, gender and fractional anisotropy were entered in a first step
using the brain region (normal appearing white matter, outer T2
perilesion layer and inner T2 perilesion layer) as dependent
variable. We chose the fractional anisotropy measure, as it is
the most widely used measure from DTI to assess microstruc-
tural changes in white matter. The second step added DVR in
order to evaluate the additional value of such measure in dis-
tinguish between the aforementioned brain regions. The asso-
ciation between [18F]florbetapir DVR and cortical and NAWM
normalized volume was assessed through a mixed-effect linear
model including mean T1 and T2 lesions DVR as the factor of
interest, age and gender as covariates, the subject as the random
effect, and the cortical and NAWM normalized volume as the
dependent variable.
The cerebral blood flow in NAWMwas compared to intact
and damaged white matter tissue using a mixed-effect linear
model using regions of interest (MS patients’NAWM, healthy
controls’ white matter, impaired white matter, unaffected
white matter) as factors of interest, and the cerebral blood flow
as the dependent variable to explore how cerebral blood flow
changes in brain regions with damaged myelin.
The diagnostic accuracy for both SUVand DVR in classi-
fying white matter tissue as belonging to NAWM or
demyelinated tissue (namely, the manually definedT2 lesions)
was estimated through a receiver operating characteristic anal-
ysis for DVR and SUV70–90 and a comparison between the
two areas under the curve was performed. We tested the dif-
ference between the SUV in the cerebellum cortex for MS
patients and healthy controls through an unpaired two-tailed
Student-t test. We also explored the correlation between DVR
and SUV70–90 in NAWM, T2 and T1 lesion through a linear
regression including T2 and T1 lesions mean SUV as the
factor of interest, age and gender as covariates DVR as the
dependent variable.
The correlation between DVR in both T2 lesions and black
holes and physical disability assessed through the expanded
disability status scale, the timed 25-ft walk and the 9-Hole-Peg
test, and disease severity assessed through the MS severity
score, was evaluated through a linear regression including
T2 and T1 lesions mean DVR as the factor of interest, age
and gender as covariates and the clinical outcome as the de-
pendent variable. Data will be provided upon request.
All data are presented as mean ± standard deviation (SD),




Both T2 and T1 lesions showed a lower mean DVR in MS
patients compared to healthy controls’ white matter (−11.1%,
P < 0.001, −14.6%, P < 0.001 respectively; Table 2 and 3,
Fig. 1 and 2a).
None of the enrolled MS patients showed Gd + lesions. No
differences were found between mean DVR in cortical grey
matter for MS patients and healthy controls (coeff. = −0.02,
P = 0.50, confidence interval [CI] = −0.7 to 0.04) and between
NAWM in MS patients and white matter DVR in healthy
controls (coeff. = −0.05, P = 0.12, CI = −0.11 to 0.01).
Compared to healthy controls mean DVR in white matter,
lower mean DVR values were found in the outer T2
perilesional layer (8–4 mm) (−6.3%; P = 0.004), in the inner
T2 perilesional layer (4–0 mm) (−8.3%; P < 0.001), in the
outer T2 intralesional layer (−16%; P < 0.001) and in the inner
T2 intralesional layer (−18.8%; P < 0.001) (Tables 2 and 3;
Fig. 2b). At lesion-based analysis, T2 lesions intensity was
inversely correlated to the mean DVR after correction for
age and gender (r = −0.002, P < 0.001; Fig. 2c).
Similarly, T1 lesions with a lower intensity showed a lower
mean DVR after correction for age and gender (coeff. = 0.003,
P < 0.001).
Using regional classification, mean DVR in infratentorial
lesions was not different compared to mean DVR in white
matter for healthy controls. Conversely, a lower mean DVR
was found in periventricular (−18.8%; P < 0.001),
juxtacortical (−18.1%; P < 0.001) and white matter T2 lesions
(−5.6%, P = 0.04) compared to healthy controls’ white matter
mean DVR (Tables 2 and 3).
Mean T2 and T1 lesions DVR was not related to the annu-
alized relapse rate, the disease duration, the EDSS, the 9-Hole-
peg test and the MSSS after correction for age and gender.
Higher DVR within T2 lesions was associated with lower
Timed 25-ft walk time after correction for age and gender
(coeff. = − 9.42, P < 0.001).
Correlation of [18F]florbetapir PET and MRI measures
MS patients had a lower normalized NAWM volume com-
pared to healthy controls’ white matter (P = 0.001). No differ-
ences were found for cortical grey matter. Normalized cortical
grey matter and normalized white matter volume were not
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associated with the mean DVR in T2 and T1 lesions after
correction for age and gender.
Using a lesion-based approach, mean DVR in T2 and T1
lesions correlated with fractional anisotropy (coeff. = 0.47 and
coeff. = 0.50, respectively; P < 0.001),mean diffusivity (coeff.-
= −0.148 and coeff. = −0.238, respectively; P < 0.001), axial
diffusivity (coeff. = −0.123 and coeff. = −0.176, respectively;
P < 0.001) and radial diffusivity (coeff. = −0.163 and coeff. =
Table 2 Mean [18F]florbetapir DVR for each region of interest in multiple sclerosis patients and healthy controls
Region of Interest Multiple Sclerosis
patients
Healthy controls
Cortical grey matter, mean DVR± SD (Min - Max) 1.02 ± 0.06 (0.95–1.17) 1.05 ± 0.09 (0.84–1.20)
Normal appearing white matter, mean DVR± SD (Min - Max) 1.39 ± 0.05 (1.32–1.52) 1.44 ± 0.11 (1.19–1.65)
T2 lesions, mean DVR ± SD (Min - Max) 1.28 ± 0.08 (1.13–1.40) –
T1 lesions, mean DVR ± SD (Min - Max) 1.23 ± 0.08 (1.09–1.36) –
T2 mild intensity lesions, mean DVR± SD (Min - Max) 1.23 ± 0.08 (1.10–1.36) –
T2 moderate intensity lesions, mean DVR ± SD (Min - Max) 1.19 ± 0.08 (1.06–1.33) –
T2 severe intensity lesions, mean DVR ± SD (Min - Max) 1.19 ± 0.14 (0.99–1.42) –
T1 mild intensity lesions, mean DVR± SD (Min - Max) 1.37 ± 0.09 (1.23–1.61) –
T1 moderate intensity lesions, mean DVR ± SD (Min - Max) 1.26 ± 0.08 (1.12–1.40) –
T1 severe intensity lesions, mean DVR ± SD (Min - Max) 1.11 ± 0.12 (0.83–1.35) –
Outer T2 perilesion layer (8–4 mm), mean DVR ± SD (Min - Max) 1.35 ± 0.05 (1.27–1.45) –
Inner T2 perilesion layer (4–0 mm), mean DVR ± SD (Min - Max) 1.32 ± 0.05 (1.22–1.41) –
Outer T2 intralesional layer, mean DVR± SD (Min - Max) 1.21 ± 0.08 (1.08–1.33) –
Inner T2 intralesional layer, mean DVR± SD (Min - Max) 1.17 ± 0.10 (1.01–1.37) –
Infratentorial, mean DVR ± SD (Min - Max) 1.37 ± 0.13 (1.13–1.55) –
Periventricular, mean DVR ± SD (Min - Max) 1.17 ± 0.09 (1.02–1.35) –
Juxtacortical, mean DVR ± SD (Min - Max) 1.18 ± 0.15 (0.85–1.44) –
White matter lesions, mean DVR± SD (Min - Max) 1.36 ± 0.06 (1.27–1.49) –
DVR =Distribution Volume Ratio; SD = Standard Deviation
*Only one patient presented a single gadolinium-enhancing lesion
Table 3 Differences in mean
[18F]florbetapir DVR between
regions of interest in multiple
sclerosis patients and mean DVR
in white matter for healthy
controls
Independent variables Coefficient β SE 95% CI z P
Normal appearing white matter - 0.04 0.03 - 0.10 0.02 - 1.38 0.17
T2 lesions - 0.15 0.03 - 0.21 - 0.10 - 5.15 <0.001
T1 lesions - 0.20 0.03 - 0.26 -0.14 - 6.71 <0.001
T2 mild intensity lesions - 0.11 0.04 - 0.18 - 0.04 - 3.00 0.003
T2 moderate intensity lesions - 0.23 0.04 - 0.28 - 0.10 - 6.44 <0.001
T2 Severe intensity lesions - 0.24 0.04 - 0.31 - 0.16 - 6.49 <0.001
T1 mild intensity lesions - 0.07 0.03 - 0.17 0.00 - 1.88 0.06
T1 moderate intensity lesions - 0.18 0.03 - 0.25 - 0.11 - 4.97 <0.001
T1 Severe intensity lesions - 0.32 0.03 - 0.39 - 0.26 - 9.30 <0.001
Outer T2 perilesional layer (8–4 mm) - 0.09 0.03 - 0.15 - 0.03 - 2.86 0.004
Inner T2 perilesional layer (4–0 mm) - 0.12 0.03 - 0.18 - 0.06 - 3.89 <0.001
Outer T2 intralesional layer - 0.22 0.03 - 0.28 - 0.16 - 7.24 <0.001
Inner T2 intralesional layer - 0.25 0.03 - 0.31 - 0.19 - 8.34 <0.001
Infratentorial - 0.07 0.04 - 0.15 0.01 - 1.79 0.07
Periventricular - 0.28 0.04 - 0.35 - 0.20 - 7.01 <0.001
Juxtacortical - 0.26 0.04 - 0.34 - 0.18 - 6.58 <0.001
White matter lesions - 0.08 0.04 - 0.16 - 0.01 - 2.09 0.04
Values are adjusted for age and gender. SE = Standard Error, CI = Confidence Interval; DVR =Distribution
Volume Ratio
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−0.227, respectively; P < 0.001) (Fig. 3a). DVR resulted to be
more sensitive to brain damage when compared with fractional
anisotropy. Specifically, the model for predicting brain dam-
aged areas (normal appearing white matter, outer T2 perilesion
layer and inner T2 perilesion layer) including DVR (R2 = 0.39,
F = 1.94, with coeff. For DVR = -1.81, CI = −3.59 to −0.02,
namely the inner the T2 lesion we go the lower the DVR value)
was more sensitive than the model only including fractional
anisotropy (R2 = 0.04, F = 0.19) (P = 0.04).
Mean CBF was not different between unaffected MS pa-
tients’ white matter areas and healthy controls’ white matter
(31.31 ± 6.53 and 33.73 ± 6.50, P > 0.05). Conversely, mean
CBF was significantly reduced in impaired white matter tissue
compared to NAWM in MS patients (% reduction in mean
CBF was 10.9%, P = 0.005; Fig. 3b).
Comparison between [18F]florbetapir SUV, SUVR
and DVR
All the previous analyses were performed using the SUV70–90
as dependent variables instead of mean DVR.We found similar
results to those obtained using mean DVR (data not shown).
However, when evaluating the SUV70–90 in the cerebellar cor-
tex for MS patients and healthy controls to perform the SUVR
analysis, we found that SUV70–90 was lower in the cerebellar
grey matter for MS patients compared to healthy controls (P =
0.04; Fig. 4). Therefore, we did not perform the analysis using
the SUVR as measure of tracer binding. The comparison be-
tween the receiving-operator curves for DVR and SUV in dis-
tinguish between NAWM and demyelinated lesions as detected
through T2 MRI sequence revealed no difference (area under
the curve 0.77 and 0.66, respectively; P value for ROC curves
comparison = 0.26). Moreover, DVR correlated with SUV in
NAWM (coeff. = 0.06, P = 0.03), T2 and T1 lesions (coeff. =
1.70 and coeff. = 0.21, respectively; P < 0.001).
Discussion
In this study, we demonstrated that [18F]florbetapir PET is a
valid tool to detect the pattern of demyelination in MS, with a
comparable accuracy between SUV70–90 PETmeasure and the
computational DVR analysis methods. Combining PET with
advanced MRI techniques, we showed that myelin damage
was correlated with microstructural white matter changes
and lower perfusion rate, providing additional information.
We showed that [18F]florbetapir binding from dynamic
DVR and static SUV measures have comparable accuracy in
differentiating myelin damaged tissue from NAWM.
[18F]florbetapir quantification with SUV has a number of ad-
vantages including short scan-time, with acquisition within a
predefined time window and lower costs compared to the
dynamic continuous acquisition. Bodini and colleagues
demonstrated that longitudinal [11C]PIB PET imaging scans
quantified through the DVR, might depict not only demyelin-
ation but also remyelination over time [15]. Hence SUV mea-
sures could be helpful when assessing treatment efficacy in
clinical trials and in the management of patients with MS.
However, the longitudinal reproducibility of Logan DVR
and SUV for [18F]florbetapir PET might deserve further stud-
ies to be confirmed.
We showed that [18F]florbetapir binding was decreased in
focal white matter lesions of the MS patients, defined on con-
ventional MRI, compared to the tracer uptake in the white
matter of the healthy controls. T1 lesions showed the lowest
value, confirming that they are characterized by extensive
myelin destruction [29]. Post-mortem studies have already
reported that T1 hypointensity reflects histopathological mod-
ifications, such as axonal loss, extracellular oedema and de-
myelination [30]. The extent of each of these pathological
processes could not be evaluated through conventional MRI.
To overcome this obstacle, several advanced MRI techniques
have been applied in MS. Among them, the diffusion tensor
imaging is the most promising technique to assess microstruc-
tural changes while measuring the water motility within tis-
sues. However, the diffusion tensor imaging measures the
global structural modifications within damaged tissues includ-
ing demyelination, axonal damage, microglia activation [31]
and gliosis without being able to differentiate them [32, 33].
[18F]florbetapir PET imaging can measure the extent of demy-
elination without including biases from other pathological
changes, such as gliosis or axonal loss, and we demonstrated
that DVR provides additional information on tissue damage
compared to DTI measures. Further studies including other
advanced MRI techniques such as magnetization transfer im-
aging might also evaluate the specificity of PET imaging over
MRI in detecting demyelination.
[18F]florbetapir binding was similar for MS patients and
healthy controls in NAWM. The absence of difference in my-
elin content of grey and white matter that we found for the two
groups appears not to be in line with previous studies that have
shown tissue changes within both grey and white matter out-
side the lesions detected by conventional MRI through diffu-
sion tensor imaging, magnetisation transfer imaging and spec-
troscopy [32, 34–36]. However, this discrepancy further un-
derlines that such MRI techniques are able to detect global
pathological changes, including axonal degeneration, gliosis
and inflammation throughout the brain, but are not specific
measures of myelin integrity. Noteworthy, it is also important
to underline that demyelination arises to different extent from
neuroinflammation. Therefore, although microglia activation
was reported throughout the normal appearing white matter
[37], demyelination might not occur simultaneously.
However, we reported that the white matter tissue surrounding
the edge of demyelinating lesions, detected through conven-
tional MRI, is also affected by demyelination at different
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degrees. A post-mortem study by De Groot and colleagues
reported reduced myelin density in areas in close proximity
to the demyelinating damaged areas in brain specimens from
MS patients [30]. Furthermore, Bodini and colleagues report-
ed a similar pattern of demyelination through a [11C]PIB PET
imaging study [15]. In this latter study, authors evaluated up to
2 mm rim surrounding T2 lesions. Here, we reported that
myelin disruption is a process going further beyond the bor-
ders detected through conventional MRI images, up to almost
1 cm. This aspect is important when assessing the extent of
demyelination throughout the CNS. Slowly evolving lesions
are becoming a hallmark for disease progression in MS [38].
Noticeably, our finding suggested that [18F]florbetapir PET
imaging might detect with a single scan a larger areas of dam-
aged tissue compared to conventional MRI and, thus, might
be considered a better predictor of disease progression.
Moreover, the increased size of a lesion may also depend on
an ineffective and incomplete process of remyelination and
does not necessarily implies the reactivation of the lesion.
Interestingly, longitudinal [18F]florbetapir PET scans might
shed further light in the biological bases of the remyelinating
process around the lesions.
We would expect a difference in cortical grey matter
[18F]florbetapir binding between MS patients and healthy
controls, because cortical demyelinating lesions are becoming
a hallmark in MS pathology [36]. According to this hypothe-
sis, we found that the myelin content within the cerebellar
cortex for MS patients was lower than the one in the cerebellar
cortex of healthy controls. This finding also highlight that the
cerebellum grey matter cortex must not be chosen as reference
region for amyloid-β PET imaging in MS as opposed to other
neurodegenerative disorders, such as Alzheimer’s disease [39,
40]. This caveat also confirms that the supervised cluster anal-
ysis is crucial when selection of the reference region is needed.
Moreover, as previously stated, also SUV could be helpful
when assessing treatment efficacy; however, its longitudinal
reproducibility should to be explored. The extent of demye-
lination within both T2 and T1 lesions was not associated with
cortical or white matter volume. Although several studies
have pointed out that the lesion load measured through con-
ventional MRI correlates with the grey matter volume in MS
[41, 42], our results suggested that demyelination specifically
measured with [18F]florbetapir PET imaging within MS le-
sions per-se is not the cause of brain atrophy. Supposedly,
the balance between remyelination, preserved axonal integrity
and the wallerian degeneration of axons traversing lesions
might impact the total brain volume and the cortical thickness
[43]. Moreover, axonal injury in MS is not restricted to white
matter lesions but can occur also in the NAWM, independent-
ly from focal cerebral demyelination [35]. Therefore, longitu-
dinal amyloid-β PET imaging studies, eventually coupled
with [11C]flumazenil PET, specifically measuring neurode-
generation [44], are needed to further elucidate the impact of
demyelination throughout the CNS on brain and cortical axo-
nal loss. In addition, a combined [11C]flumazenil and
amyloid-β PET imaging study might also shed further light
on the interplay between demyelination, eventually
remyelination and axonal degeneration. A recent paper, using
a complex approach involving optical coherence tomography,
conventional and advanced MRI, reported that demyelination
over a specific white matter tract (i. e. optic radiation) precedes
neurodegeneration [45]. Using a PET approach using two
probes specifically targeting the two main pathological pro-
cesses occurring in MS patients, might provide the unique
opportunity to evaluate the dynamics of such processes with
a high degree of specificity and to evaluate the impact of the
interplay between these two phenomena on clinical disability.
We observed a reduced cerebral arterial blood perfusion in
white matter regions with a higher extent of demyelination.
MS lesions and normal appearing white matter are character-
ized by cerebral hemodynamic impairment even in absence of
blood-brain-barrier damage [46], resulting in reduced arterial
Fig. 1 [18F]Florbetapir PET and MRI images from a Multiple Sclerosis
patient. 3D-T1w MPRAGE image (a), FLAIR image (b) [18F]florbetapir
distribution volume ratio (DVR) parametric map (c) for a 54-year-old
female relapsing-remitting Multiple Sclerosis patient (disease duration =
10 years; Annualized-Relapse-Rate of 0.3; EDSS = 3.5; and MSSS =
4.55). Arrows point to T1 lesions (a) and T2 lesions (b) showing a
reduced [18F]florbetapir binding in the DVR parametric map (c). Colour
bar reflects range of [18F]florbetapir DVR. Arrows point to demyelinating
lesion, with both the lesion (in blue) and perilesional rim (in green). In
perilesional area (up to 8 mm) DVR values were reduced compared with
the white matter as defined through standard MRI in healthy controls
(estimated 7% loss, P < 0.01)
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blood supply. Previous pathological studies have already re-
ported hemodynamic changes in MS including vessels’
thrombosis and tissue hypoxia due to fibrin deposition in de-
myelinating plaques. Specifically, the high venular density
and the reduced arterial flow in the damaged white matter
tissue suggest that hemodynamic changes could contribute
to tissue damage. Yet, the precise impact of vascular factors
onMS pathology has not been fully elucidated. Our data about
cerebral blood flow are partly in line with previous findings,
especially when compared with studies using the same meth-
odology [47, 48], which will further support the impact of
vascular changes on MS pathology. Longitudinal PET/MRI
studies could further investigate whether arterial blood flow
reduction is the primary cause or the result of the
inflammatory-driven tissue necrosis. It is worthy to mention
that both DVR and SUV depend on an intact blood-brain bar-
rier and changes in blood-brain barrier integrity occurring in
gadolinium enhancing lesions could potentially introduce a bi-
as. However, in the present study only one single gadolinium
enhancing lesion was present in one patient and, in addition,
DVR is a dynamic measure which take into account the time
activity curve of tracer distribution. Furthermore, changes in
CBF do not appear to have a significant effect on DVR values
estimated using nonlinear modelling or graphical analysis [49].
Therefore, [18F]florbetapir DVR measures are unlikely to be
significantly influenced by cerebral arterial blood perfusion.
We did not find any correlations between the extent of white
matter lesions demyelination and the disease severity, assessed
through theMSSS, disease duration and annualized relapse rate
and physical disability assessed through the EDSS. However,
we found a correlation between physical disability assessed
through the Timed 25-ft walk and the extent of myelin loss
within T2 lesions. Bodini and colleagues showed that both
the EDSS and the MSSS were not related to the tracer DVR
in T2 lesions at a cross-sectional evaluation [15]. Physical dis-
ability was rather related to the extent of lesions demyelination
over a follow-up period of four months [15]. We might specu-
late that physical disability is actually driven by the balance
between demyelination and remyelination within MS lesion
with a consequent axonal loss. Moreover, EDSS is a measure
of physical disability with a low degree of specificity because it
is mainly related to walking abilities, especially when it turns to
the highest point. Timed 25-ft walk is actually more precise
than EDSS and might explain the discrepancy in our finding.
In conclusion, our study reported that [18F]florbetapir PET
imaging might be able to assess in vivomyelin pathology with
a higher extent of specificity compared to MRI. The static
SUV70–90 PET imaging evaluation provides similar
Fig. 2 Relationship between [18F]florbetapir PET and T1 and T2 white
matter lesions. (a) Scatter plot diagram showing mean [18F]florbetapir
distribution volume ratio (DVR) and standard deviation in white matter
for healthy controls and in normal appearing white matter, T2 lesions and
T1 lesions in Multiple Sclerosis patients. Mean DVR decreased from
normal appearing white matter to T2 lesions and the lowest value was
found in T1 lesions. ** P < 0.001, paired two-tailed student’s t test. (b)
Scatter plot diagram shows mean DVR and standard deviation in white
matter for healthy controls and in normal appearing white matter, outer
T2 perilesional layer (8–4mm), inner T2 perilesional layer (4–0mm), outer
T2 intralesional layer, middle T2 intralesional layer and inner T2
intralesional layer for Multiple Sclerosis patients. Mean DVR values
decreased from normal appearing white matter to the center of T2 lesions.
** P < 0.001, paired two-tailed student’s t test. (c) Scatter plot diagram
showing the correlation between mean DVR and T2 lesions intensity.
Coefficient and P value were calculated using a mixed-effect linear model
including each lesion’s intensity as factor of interest, age and gender as
covariates, subject identification number as random effect and each
lesion’s DVR as dependent variable. The scatter plot displays a direct cor-
relation between T2 lesion intensity and mean DVR values (coeff. = −
0.002, P < 0.001). Lower DVR values were found in brighter lesions
R
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Fig. 3 Relationship between
[18F]florbetapir PET and
advanced MRI measures. (a)
Scatter plot diagram displays the
relationship between mean
[18F]florbetapir distribution
volume ratio (DVR) and
fractional anisotropy, mean, axial
and radial diffusivity in T2
lesions. DVR decreased
significantly in lesions with lower
fractional anisotropy (coeff. =
0.47, P < 0.001) and increased in
lesions with higher mean
diffusivity (coeff. = −0.148, P <
0.001), axial diffusivity (coeff. =
−0.123, P < 0.001) and radial dif-
fusivity (coeff. = −0.163, P <
0.001). (b) Scatter plot diagram
shows mean cerebral blood
perfusion and standard deviation
in white matter for healthy
controls and in normal appearing
white matter, unaffected white
matter and impaired white matter
for Multiple Sclerosis patients.
Impaired white matter areas
showed a significantly lower
perfusion. ** P < 0.001, paired
two-tailed student’s t test
Fig. 4 Mean [18F]florbetapir SUV70–90 in cortical grey matter. Cortical
regions showing a mean SUV70–90 lower than the calculated cut-off for
normal cortical myelination. (a) Healthy 38-year-old female and (b) 44-
year-old female relapsing-remitting Multiple Sclerosis patient (disease
duration = 18 years; Annualized-Relapse-Rate of 0.22; EDSS = 1;
MSSS = 0.26). Cut-off was calculated as the mean of SUV70–90 in the
cortical grey matter for healthy controls – 1.96 times standard deviation,
which corresponds to the 5th percentile. Calculated cut-off was 1.0246.
Images presented on the International Consortium for Brain Mapping
(ICBM) whole brain surface visualized in BrainNet Viewer (http://
www.nitrc.org/projects/bnv/); colour bar represents Z-scores
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information to the dynamic PET. Dynamic PET imaging re-
quires long dynamic scans and, hence, high costs. Conversely,
the SUV might be calculated through a static acquisition last-
ing for twenty minutes. This makes the technique highly ap-
pealing to implement in clinical settings. Clinicians could use
the PET imaging as a tool to measure the subjective
remyelinating potential, with the ultimate goal of personaliz-
ing treatment. They could also rely on its quantitative mea-
sures when assessing the effect of a drug targeting
remyelination, e.g. opicinumab [50]. Finally, although further
longitudinal evaluations are needed to test the reproducibility
of the technique, measures derived from PET imaging (mean
DVR or mean SUV) are able to measure the accumulation of
tissue changes beyond the defined borders of the lesion.
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